SG11202004698RA - Process for the preparation of drug linker compounds - Google Patents

Process for the preparation of drug linker compounds

Info

Publication number
SG11202004698RA
SG11202004698RA SG11202004698RA SG11202004698RA SG11202004698RA SG 11202004698R A SG11202004698R A SG 11202004698RA SG 11202004698R A SG11202004698R A SG 11202004698RA SG 11202004698R A SG11202004698R A SG 11202004698RA SG 11202004698R A SG11202004698R A SG 11202004698RA
Authority
SG
Singapore
Prior art keywords
preparation
drug linker
linker compounds
compounds
drug
Prior art date
Application number
SG11202004698RA
Inventor
Sophie Blanchard
James Coats
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11202004698RA publication Critical patent/SG11202004698RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
SG11202004698RA 2017-11-30 2018-11-29 Process for the preparation of drug linker compounds SG11202004698RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593104P 2017-11-30 2017-11-30
PCT/US2018/063070 WO2019108797A1 (en) 2017-11-30 2018-11-29 Process for the preparation of drug linker compounds

Publications (1)

Publication Number Publication Date
SG11202004698RA true SG11202004698RA (en) 2020-06-29

Family

ID=66665808

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004698RA SG11202004698RA (en) 2017-11-30 2018-11-29 Process for the preparation of drug linker compounds

Country Status (14)

Country Link
US (2) US11612666B2 (en)
EP (1) EP3717016A4 (en)
JP (2) JP7402159B2 (en)
KR (1) KR20200094185A (en)
AU (1) AU2018375412A1 (en)
BR (1) BR112020010503A2 (en)
CA (1) CA3082165A1 (en)
EA (1) EA202091340A1 (en)
IL (1) IL274757A (en)
MA (1) MA51870A (en)
MX (1) MX2020005565A (en)
SG (1) SG11202004698RA (en)
WO (1) WO2019108797A1 (en)
ZA (1) ZA202003037B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020233174A1 (en) 2019-05-20 2020-11-26 烟台迈百瑞国际生物医药有限公司 One-pot preparation process for antibody drug conjugate intermediate
CN110945009B (en) * 2019-10-23 2023-10-31 烟台迈百瑞国际生物医药股份有限公司 Oligopeptide connector intermediate and preparation method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
BR122018071808B8 (en) * 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
JP2009507980A (en) 2005-09-14 2009-02-26 ユセベ ファルマ ソシエテ アノニム Comb polymer
AU2007296056B2 (en) 2006-09-15 2012-09-13 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
WO2009002427A2 (en) * 2007-06-21 2008-12-31 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
CN103717595A (en) * 2011-05-27 2014-04-09 Ambrx公司 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
CN104640572B (en) * 2012-05-15 2018-04-27 索伦托医疗有限公司 Drug conjugates, coupling method, and application thereof
CN107629059B (en) * 2012-12-07 2020-07-28 沃泰克斯药物股份有限公司 Compounds useful as inhibitors of ATR kinase
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
US9533483B2 (en) 2014-09-26 2017-01-03 Kimberly-Clark Worldwide, Inc. Apparatus for and method of shaping and applying a segment to a moving web

Also Published As

Publication number Publication date
EP3717016A1 (en) 2020-10-07
WO2019108797A1 (en) 2019-06-06
US20200360532A1 (en) 2020-11-19
CA3082165A1 (en) 2019-06-06
JP7402159B2 (en) 2023-12-20
ZA202003037B (en) 2023-12-20
KR20200094185A (en) 2020-08-06
MA51870A (en) 2020-10-07
MX2020005565A (en) 2020-08-20
EA202091340A1 (en) 2020-10-16
CN111417408A (en) 2020-07-14
AU2018375412A1 (en) 2020-05-28
US20240042052A1 (en) 2024-02-08
JP2023164652A (en) 2023-11-10
BR112020010503A2 (en) 2020-10-20
US11612666B2 (en) 2023-03-28
JP2021505542A (en) 2021-02-18
EP3717016A4 (en) 2021-09-01
IL274757A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
ZA201706795B (en) Process for the preparation of dicycloplatin
IL265239A (en) Process for the manufacture of a solid pharmaceutical composition
GB201709652D0 (en) Pharmaceutical compounds
IL267508B (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
IL260465B (en) Process for the preparation of an antibody-rifamycin conjugate
GB201704965D0 (en) Pharmaceutical compounds
GB201704714D0 (en) Pharmaceutical compounds
GB201703881D0 (en) Pharmaceutical compounds
GB201706806D0 (en) Pharmaceutical compounds
GB201704966D0 (en) Pharmaceutical compounds
IL274757A (en) Process for the preparation of drug linker compounds
IL275480A (en) Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
IL268835B (en) Process for the preparation of 2-cyanoimidazole compounds
IL275381A (en) A process for the preparation of crisaborole
ZA202002116B (en) Process for the preparation of piperine
HRP20181918T1 (en) Process for the synthesis of benzazepine derivatives
IL274560A (en) Process for the preparation of raltegravir
HK1252354A1 (en) Process for the preparation of amphiphilic imidazolinium compounds
HK1258181A1 (en) Process for the preparation of a quelating agent
PL3728220T3 (en) Pharmaceutical compounds
GB201717005D0 (en) Pharmaceutical compounds
GB201711704D0 (en) Pharmaceutical compounds
GB201700867D0 (en) Pharmaceutical compounds